Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



FDA Rejection. EU Withdrawal. Set and Match?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Following a Food and Drug Administration rejection earlier in the year, ARIAD Pharmaceuticals' (Nasdaq: ARIA  ) partner Merck (NYSE: MRK  ) has withdrawn its application for approval of their cancer drug ridaforolimus in the European Union. Merck withdrew the application after the reviewers made it clear the drug wasn't going to get approved, a pretty standard operating procedure for drugs about to be rejected in the EU.

Is ridaforolimus dead? In soft tissue sarcoma or bone tumors, perhaps. The drug seems to work, offering a 21% improvement in progression-free survival. Unfortunately, that equates to just 3.1 weeks, causing the side effects to become a more important aspect of the risk-benefit analysis. Both agencies apparently thought the arbitrary analysis didn't tip the scale in favor of using the drug, at least for those indications.

Merck is testing ridaforolimus in other cancer types including breast cancer, a pretty large market. Only time will tell, but investors shouldn't count the drug out for those added indications. Ridaforolimus works in the same way as Pfizer's (NYSE: PFE  ) Torisel and Novartis' (NYSE: NVS  ) Afinitor, which are both approved for treating kidney cancer; Merck is testing the drug against that tumor type as well.

Neither company is completely dependent on ridaforolimus getting approved. Merck is obviously a large company with multiple different opportunities. And ARIAD has a date with destiny in March as the FDA reviews its leukemia treatment ponatinib, although the decision could come even earlier give the rolling submission.

An approval for ponatinib looks pretty likely. In patients that failed Novartis' Tasigna, or Otsuka (OTC: OTSKF) and Bristol-Myers Squibb's (NYSE: BMY  ) Sprycel, or who have a mutation that doesn't allow them to be treated with those drugs -- in other words their running out of options -- the drug produced a major cytogentic response in more than half of the patients.

For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. Will Merck crumble under its own weight, or will it continue to pay dividends to investors for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand new premium research report today. I walk you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2132903, ~/Articles/ArticleHandler.aspx, 10/21/2016 9:24:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 12 hours ago Sponsored by:
DOW 18,162.35 -40.27 0.00%
S&P 500 2,141.34 -2.95 0.00%
NASD 5,241.83 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/20/2016 4:00 PM
ARIA $10.78 Down +0.00 +0.00%
Ariad Pharmaceutic… CAPS Rating: **
MRK $61.92 Down +0.00 +0.00%
Merck and Co. CAPS Rating: ****
BMY $50.36 Down +0.00 +0.00%
Bristol-Myers Squi… CAPS Rating: ****
NVS $75.92 Down +0.00 +0.00%
Novartis CAPS Rating: ****
PFE $32.54 Down +0.00 +0.00%
Pfizer CAPS Rating: ****